We are conducting an open-label multicentre phase II study to evaluate the efficacy and safety of the combination therapy of XELOX and bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer. The primary endpoint of the study is progression-free survival. The secondary endpoints are the toxicity, overall response rate, time to treatment failure and overall survival. Thirty-five patients are required for the study.
INTRODUCTION
5-Fluorouracil (5-FU) in combination with leucovorin (LV) (5-FU/LV) has been the standard systemic regimen for the treatment of unresectable advanced/recurrent colorectal cancer in most countries (1) (2) (3) (4) . Recently, more effective chemotherapies that include oxaliplatin or irinotecan {e.g. FOLFOX [folinic acid (FOL), 5-fluorouracil (F) and oxaliplatin (OX)], XELOX (capecitabine plus oxaliplatin) (5 -13) or FOLFIRI [folinic acid (FOL), 5-fluorouracil (F) and irinotecan (IRI)] therapy (12) (13) (14) (15) } have shown superior survival benefit when compared with 5-FU/LV, and led to a steady improvement in the median overall survival of patients with unresectable advanced/recurrent colorectal cancer. Many randomized clinical trials have shown the advantages of combining bevacizumab with 5-FU/LV (16, 17) , IFL [irinotecan (I), bolus-5-fluorouracil (F) and leucovorin (L)] (18) or FOLFOX4/XELOX (19, 20) ; combinations of chemotherapeutic agents and monoclonal antibodies are used as standard first-line treatment.
With the increase in average life expectancy, the incidences of colorectal cancer among elderly people are gradually increasing in Japan, and this is an important issue in the field of solid tumours. A meta-analysis by Cassidy et al. (21) showed that age groups and the add-on treatment had no effect on the overall survival rate after treatment with bevacizumab [hazard ratio ¼ 0.80 (95% confidence interval, 0.74 -0.87) for all populations and 0.85 (0.74 -0.97) for ages over and equal to 65 years]. On the other hand, it is well known that neutropenia occurs more frequently after FOLFOX therapy than after XELOX in elderly individuals (19, 20, 22) . Furthermore, since capecitabine can be orally administered, XELOX therapy can be considered to be more favourable for elderly patients. However, there is no evidence of the safety and efficacy of the combination of chemotherapeutic agents and bevacizumab in elderly patients aged 75 years or more (officially referred to as 'late-stage elderly' by the Japanese government) with colorectal cancer. 
ENDPOINTS
The primary endpoint is progression-free survival (PFS). The secondary endpoints are the toxicity, overall response rate, time-to-treatment failure and overall survival. The progression will be evaluated based on response evaluation criteria in solid tumours (RECIST) ver.1.1 (23) . 
TREATMENT METHODS
The treatment schedule of the combination therapy of XELOX and bevacizumab applied in this study is shown in Table 1 . One cycle is conducted from day 1 to day 22. This treatment protocol is continued until disease progression is arrested or the patients can be operated on. The dose reduction or stopping criteria of drugs due to adverse events is defined based on the haematological toxicity (Grade 4 neutropenia, Grade 3 neutropenia with 38.58C or Grade 3 or more decrease in platelets) and Grade 3 non-haematological toxicity. Oxaliplatin will be stopped in case Grade 3 or more allergies occur, and reduced in case peripheral sensory neuropathy occurs. Capecitabine will be reduced in case the hand-foot syndrome occurs.
The protocol treatment will be discontinued if the following are observed: (i) inability to continue the protocol treatment because of an adverse drug reaction; (ii) an adverse drug reaction is causing the patient to refuse treatment; (iii) an adverse drug reaction is causing the clinician to discontinue treatment; (iv)death or (iv) protocol violation or the patient becomes ineligible after enrolment.
FOLLOW-UP
The ASCA Trial schedule and its data collection are shown in Table 2 . Disease progression and occurrence of new diseases are monitored by using abdominal radiography, abdominal computed tomography (CT) or magnetic resonance imaging and thoracic CT, and by measuring levels of the tumour markers CEA and CA19 -9 at the baseline and every 8 weeks during the treatment period (tumour markers levels are measured every 4 weeks). Blood tests and symptom checks (collecting adverse events) will be carried out throughout the treatment period. The follow-up period is 1 year after the registration of the last patient.
STUDY DESIGN AND STATISTICAL METHODS
This study was primarily designed to evaluate the effect of the combination therapy of XELOX and bevacizumab on PFS.
The NO16966 trial reported a median PFS of 9.4 months for the FOLFOX/XELOX treatment in combination with 136 XELOX with bevacizumab for colorectal cancer bevacizumab (11) . In Japan, the JO19380 trial reported a median PFS of 11.0 months for the XELOX treatment in combination with bevacizumab (24) . Taking these data into account, it was determined that the threshold and expected PFS of the present study would be 6.5 months and 10.5 months, respectively. On the basis of the assumptions of uniform accrual over time, no loss to follow-up, and exponentially distributed survival times under a 2-year enrolment period and 1 year of follow-up, 32 patients would be needed to achieve a power of 80% with one-sided significance of P , 0.05 (25) . Taking possible dropouts into consideration, the target number of patients was set at 35. The primary analysis in this study is aimed at estimating the median PFS. The PFS curves are constructed as time-to-event plots by using the Kaplan -Meier method (26) , and the median PFS and its 95% confidence interval are estimated. Other time-to-endpoint data (overall survival and time to treatment failure) are also analysed in the same manner. The response rate and the toxicities are calculated as proportions with exact confidence intervals. 
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